Executive Profiles

Six years in, Pharm Exec looks at the progress of the International Rare Diseases Research Consortium-an ambitious global effort focused on accelerating orphan disease diagnosis, and ultimately enabling better treatment options for these underserved patient populations.

Pharm Exec talks to Hugo Fry, Sanofi’s General Manager for the UK and General Manager for Sanofi Pasteur UK and Ireland, about his vision for the company and the vaccine space in these markets.

Pharm Exec speaks to Chris Molloy, CEO of the newly established Medicines Discovery Catapult, which aims to establish new approaches to grow and sustain the UK's reputation for innovative, fast-to-patient drug discovery.

Pharm Exec talks to Mel Formica, Takeda’s Vice President of Global Market Access, about what he sees as the challenges and opportunities in 2017, and how he envisions the industries market access capabilities evolving.

Pharm Exec speaks to ICON's Ramita Tandon about how the UK and European regulators' market access plans for 2017 will affect the industry.

Pharm Exec speaks with Spanish-born Belén Garijo, CEO of Merck KGaA, Darmstadt, Germany’s healthcare business, who shares her steady-eyed approach in transforming a traditional pharma unit focused on small molecules for chronic disease to a high-tech specialty producer of immunotherapy drugs for rare cancers.

Anthony Arnold offers an overview and update of bioelectronic medicine.

Pharm Exec sits down with veteran journalist Paula Apsell, the driving force behind the long-running PBS science series NOVA. Apsell offers straightforward advice to the biopharma industry: make your business a business of inspiration, where the return is measured in passion-and the sheer, simple pleasure of finding things out.

The FDA’s Dr. John Whyte offers his perspectives on patient centricity and the issues that FDA and industry are facing.

Highlights from Peter Young's conversation with Dr. Steven Miller, Chief Medical Officer and SVP of Express Scripts, on Miller's business philosophy and the current issues facing the sector.

Pharm Exec sits down with Jeremy Desai, CEO of Apotex, Canada’s largest producer of generic drugs, to discuss the local impact of mounting pricing pressure-and how smaller and independent companies can survive in an era of consolidation and growing competition.

Founder and CEO, Bloodbuy

President, Global Vaccines, Merck & Co.

Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation

Vice President and Head, Innovation Center, Global Health and Value, Pfizer Inc.

President, US Pharmaceuticals, Bayer

Senior Director of Sales Analytics and Operations, Gilead Sciences

Vice President, Business and Financial Planning, Merck & Co.

Vice President, US Payer & Institutional Strategy Lead, Shire

Pharm Exec’s 9th annual list of rising industry leaders illustrates how the deployment of essential human capital has changed in line with a business model that is no longer static and predictable-or complacent.

Global Head, Drug Development, and Chief Medical Officer, Novartis

Vice President, Business Development, Regeneron Pharmaceuticals

Co-Founders, twoXAR

Vice President, Business Technology, Pfizer Inc.

Pharm Exec sits down with UBC President Patrick Lindsay to provide some real-world context around our 2016 feature profile of sixteen Emerging Leaders in biopharma.